This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Chronic kidney disease
  • /
  • SGLT2 inhibition and chronic kidney disease outcom...

SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond

Read time: 1 mins
Published:31st Dec 2020
Author: Tuttle KR.
Ref.:Lancet Diabetes Endocrinol. 2021 Jan;9(1):3-5.
SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond

Chronic kidney disease (CKD) is a pressing public health concern. CKD attributed to diabetes, known as diabetic kidney disease (DKD), is the most common cause of kidney failure, accounting for half of all cases. 1, 2  As the number of people with diabetes dramatically rises around the world, the burden of diabetic complications will concurrently swell. Occurring in about 30% of patients with type 1 diabetes and 40% of those with type 2 diabetes, DKD is one of most incapacitating and lethal complications of diabetes.Additionally, about a quarter of cases of kidney failure in CKD are attributed to hypertension, followed by various forms of glomerular diseases. It is crucial to recognise that the risks of CKD include a high risk of death that outcompetes risk of progression to kidney failure, particularly in patients with diabetes. 3
Indeed, most people with CKD die before progressing to kidney failure. The largest number of deaths in people with CKD are due to cardiovascular diseases, especially heart failure. 1 , 2  In order to meaningfully improve patient outcomes—survival without kidney failure or heart failure—better CKD care is urgently needed.

 Access full article